DOCSLIB.ORG

Maryland Guidelines for Prevention and Treatment of Tuberculosis 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Maryland Guidelines for Prevention and Treatment of Tuberculosis 2019 MARYLAND GUIDELINES FOR PREVENTION AND TREATMENT OF TUBERCULOSIS 2019 3rd Edition Maryland Department of Health Prevention and Health Promotion Administration Center for TB Control and Prevention Development of this document was funded, in part, by the Maryland Tuberculosis Elimination and Laboratory CDC Cooperative Agreement 5 NU52PS004690-05-00 MDH, 201 W. Preston Street ∙ Baltimore, MD 21201 ∙ health.maryland.gov ∙ Toll Free: 1-877-463-3464 ∙ TTY: 1-800-735-2258 i The use of trade names in this document is for identification purposes only and does not imply endorsement by the U.S. Public Health Service, the U.S. Department of Health and Human Services, the U.S. Centers for Disease Control and Prevention (CDC) or the Maryland Department of Health. The services and facilities of the Maryland Department of Health (MDH) are operated on a non- discriminatory basis. This policy prohibits discrimination on the basis of race, religion, color, sex, or national origin and applies to the provisions of employment and granting of advantages, privileges and accommodations. The Department, in compliance with the Americans with Disabilities Act, ensures that qualified individuals with disabilities are given an opportunity to participate in and benefit from MDH services, programs, benefits, and employment opportunities. 2019 Maryland Guidelines for the Prevention and Treatment of Tuberculosis _ Updated_November 2019 MDH, 201 W. Preston Street ∙ Baltimore, MD 21201 ∙ health.maryland.gov ∙ Toll Free: 1-877-463-3464 ∙ TTY: 1-800-735-2258 ii Maryland Guidelines for Prevention and Treatment of Tuberculosis 2019 Table of Contents page I. INTRODUCTION 1 II. ROLE OF THE LOCAL HEALTH DEPARTMENT IN TUBERCULOSIS CONTROL 2 Reporting of Cases 2 Priorities of LHD TB Control Programs 2 Nurse Case Management 3 Directly Observed Therapy 6 Video DOT (VDOT) 6 Case Reviews 6 Program Evaluation and Cohort Review 7 Contact Investigations 7 Interjurisdictional Referrals 8 Airline Contacts 9 Travel Restrictions 9 Surveillance 9 TB Research 10 Partnering with Others 10 III. PATHOGENESIS OF TUBERCULOSIS 11 IV. TUBERCULOSIS TESTING 12 Administering and Reading TB Tests 12 Mantoux Tuberculin Skin Test (TST) 12 Interpreting TST Reactions 13 Booster Phenomenon and Two-Step TST 13 Two-Step Procedure 13 Interferon Gamma Release Assay 13 Interpreting IGRA test results 14 “Convertor” vs. “Reactor” 14 2019 Maryland Guidelines for the Prevention and Treatment of Tuberculosis _ Updated_November 2019 MDH, 201 W. Preston Street ∙ Baltimore, MD 21201 ∙ health.maryland.gov ∙ Toll Free: 1-877-463-3464 ∙ TTY: 1-800-735-2258 iii Special Situations (Testing) 14 Children 14 Live-Virus Vaccinations 15 Pregnancy 15 HIV Infection 15 Individuals Born Outside the US 15 Bacille Calmette-Guerin (BCG) Vaccination 18 Immunosuppressive Treatment 18 LTBI Reporting in Maryland 19 V. TREATMENT OF LATENT TUBERCULOSIS INFECTION 19 Medical Evaluation for a Positive TST/IGRA 19 Chest Radiographs 19 HIV Testing 20 Diabetes Screening and Testing 20 Pregnancy 20 Pregnancy/Post-Partum 20 Medication Regimens for TLTBI 20 Medication Interactions 21 Children 21 Breast Feeding 21 HIV Infection 21 Renal Insufficiency and End-Stage Renal Disease 21 Contacts to Active TB Cases 21 Persons with Fibrotic Lesions 22 Suspected TB Disease Ruled Out 22 Pyridoxine Supplement (Vitamin B6) 22 Monitoring LTBI Treatment 22 Laboratory Monitoring TLTBI 23 Managing Interruptions in LTBI Treatment 23 2019 Maryland Guidelines for the Prevention and Treatment of Tuberculosis _ Updated_November 2019 MDH, 201 W. Preston Street ∙ Baltimore, MD 21201 ∙ health.maryland.gov ∙ Toll Free: 1-877-463-3464 ∙ TTY: 1-800-735-2258 iv VI. DIAGNOSIS OF TUBERCULOSIS DISEASE 26 Pulmonary 26 Extrapulmonary 26 TB Meningitis 26 Disseminated (military) TB 26 Lymphatic TB 26 Skeletal TB (bones and joints) 26 Pleural TB 26 Abdominal TB 27 Ocular TB/ TB of Reproductive Organs 27 Chest X-ray Manifestations of TB 27 Diagnostic Specimens/Laboratory Testing 27 Sputum 27 Tissue 27 AFB Smear 27 Nucleic Acid Amplification Tests 28 AFB Culture 28 AFB Culture Identification 28 Drug Susceptibility Testing 28 Molecular Detection of Drug Resistance (MDDR) 29 Submission Criteria for MDDR 29 Genotyping 29 VII. TREATMENT OF TUBERCULOSIS DISEASE 32 General Principles 32 Promoting Adherence to Treatment 32 Nurse Case Management 32 Directly Observed Therapy (DOT) 33 Video/Electronic Directly Observed Therapy 33 Enablers and Incentives 33 CTBCP Patient Consultations 34 Case and Cohort Reviews 35 CDC Centers of Excellence 35 2019 Maryland Guidelines for the Prevention and Treatment of Tuberculosis _ Updated_November 2019 MDH, 201 W. Preston Street ∙ Baltimore, MD 21201 ∙ health.maryland.gov ∙ Toll Free: 1-877-463-3464 ∙ TTY: 1-800-735-2258 v Tuberculosis Treatment Regimens 35 Intensive Phase 35 7 day per week dosing and 2017 Maryland TB Expert Panel Recommendations 36 Continuation Phase 36 Follow-up Sputum Examination 36 Sputum Culture Conversion 36 Medication Administration 37 General Principles 37 Medication Interactions 37 Methadone 37 Hormone-based Contraceptives 37 Antiretroviral Medications (ARVs) 38 Other Medication Interactions 38 Laboratory Monitoring 38 Therapeutic Drug Monitoring (TDM) 38 Monitoring Treatment of TB Disease 38 Managing Adverse Reactions 39 Gastrointestinal (GI) 39 Rash 39 Hepatitis 39 Managing Interruptions in Treatment 39 Drug Resistance or Intolerance 40 Pyridoxine (B6) Supplementation 40 Treatment Duration 41 Treatment Completion 41 Special Situations (TB Treatment) 41 Cavitary TB with Positive M. tuberculosis Cultures at 60 Days 41 Extrapulmonary TB 41 Culture-Negative (abacillary) Pulmonary TB 41 Children 42 Pregnancy 42 Congenital TB 42 Breastfeeding 42 2019 Maryland Guidelines for the Prevention and Treatment of Tuberculosis _ Updated_November 2019 MDH, 201 W. Preston Street ∙ Baltimore, MD 21201 ∙ health.maryland.gov ∙ Toll Free: 1-877-463-3464 ∙ TTY: 1-800-735-2258 vi Renal Insufficiency/ End-Stage Renal Disease 43 HIV Co-infection and Dosing Schedules 43 Immune Reconstitution Inflammatory Syndrome (IRIS) 43 Medication Reference Tables for TB Treatment (Tables 9-14, pages 44-52) 43 VIII. LEGAL ASPECTS OF TB CONTROL 53 General Principles 53 Legal Steps 53 Tuberculosis Patient/Provider Agreement for Treatment (MDH Form 4511) 53 Health Officer Order for Appropriate TB Treatment and Medical Care 54 Secretary of MDH or Health Officer Order for Medical Isolation/Quarantine 55 Violation of Order for Quarantine 55 HIPAA (Health Insurance Portability and Accountability Act) 55 IX. CONTACT INVESTIGATIONS AND TREATMENT OF CONTACTS 56 Decision to Initiate a tuberculosis (TB) Contact Investigation 56 Prioritization 56 Planning the Investigation 56 Contact Investigation Procedures 57 Medical Evaluation of High and Medium Priority Contacts 57 Treatment of Contacts 58 Contacts 2-5 years of age 58 Contacts 6 Months to 2 years of age 58 Documented Prior Positive TST or IGRA 58 Contacts with Immunosuppression 58 Source Case Investigation 58 Confidentiality 59 Use of Social Media 61 X. INFECTION CONTROL 62 Discontinuation of Airborne Infection Isolation Precautions (AII) within Hospital 62 Multi-drug Resistant TB (MDR-TB) and Extensively-drug Resistant TB (XDR-TB) 62 Discharge from Hospital 62 Admission to Long Term Care (LTC), Rehabilitation or Hospice Facilities 63 2019 Maryland Guidelines for the Prevention and Treatment of Tuberculosis _ Updated_November 2019 MDH, 201 W. Preston Street ∙ Baltimore, MD 21201 ∙ health.maryland.gov ∙ Toll Free: 1-877-463-3464 ∙ TTY: 1-800-735-2258 vii Readmission to Long Term Care (LTC) Facilities 63 Return to Work or School 63 Infection Control Plans 63 Local Health Departments 63 Long Term Care Facilitates 64 Addictions Treatment Facilities 64 Hospitals 64 Other Types of Residential Facilities 64 Recommendations for Screening, Testing and Treatment of Health Care Personnel 64 XI. TB CONTROL IN CORRECTIONAL AND DETENTION FACILITIES 67 Importance 67 Facility Risk Assessment for TB 67 TB Testing and Facility Risk 67 HIV Testing 68 Reporting 68 Airborne Infection Isolation (AII) 68 Release of Inmates with TB 68 Undocumented Persons 68 Program Evaluation 69 Contact Investigations 69 XII. NATIONAL TUBERCULOSIS INDICATORS 69 NTIP National TB Program Objectives 69 TB Program Evaluation 70 XIII. IMMIGRANT AND REFUGEE SCREENING FOR TUBERCULOSIS 70 Overseas TB Screening 70 United States TB Screening 71 Adjustment of Status 72 B-Waivers 74 2019 Maryland Guidelines for the Prevention and Treatment of Tuberculosis _ Updated_November 2019 MDH, 201 W. Preston Street ∙ Baltimore, MD 21201 ∙ health.maryland.gov ∙ Toll Free: 1-877-463-3464 ∙ TTY: 1-800-735-2258 viii REFERENCES 76 FIGURES Figure 1. Pathogenesis of TB in Untreated Immune Competent Persons Exposed to TB 11 Figure 2. Decision to initiate a tuberculosis (TB) contact investigation 60 Figure 3. Flow Chart for Assessing Priority Status of Contacts 61 Figure 4. Diagnostic Evaluation Steps for All TB B-waiver individuals 75 except persons with B0 status TABLES Table 1. Priorities for Tuberculosis Control Resource Allocation 5 Table 2. TB Risk Factors 11 Table 3. Adult Risk Groups for Targeted Testing and Treatment of LTBI 16 Table 4. Pediatric Risk Groups for Targeted Testing and Treatment of LTBI 17 Table 5. TST Cut-Points by Age for Low-Risk Persons 17 Table 6. Regimens for Treatment of Latent TB Infection/ Recommended Monitoring 24 Table 7. Components of a Tuberculosis Diagnostic Work-Up 30 Table 8. Examples of Enablers and Incentives 33 Table 9. Approved Dosing Regimens
Load more

Recommended publications
  • The Msinga Experience Lessons Learnt from South Africa 2005–2009 Contents
    TUBERCULOSIS MDR/XDR The Msinga Experience Lessons learnt from South Africa 2005–2009 Contents Summary 2 Introduction 4 The MDR/XDR TB epidemic 7 Addressing MDR/XDR TB 10 Turning the tide 15 MDR/XDR TB cases decrease 17 The way forward 20 Endnotes 21 Published in partnership with Umzinyathi District Management January 2009 TUBERCULOSIS MDR/XDR The Msinga Experience Lessons learnt from South Africa 2005–2009 © Pg-images/Dreamstime.com 1 Factors behind the decline in drug resistant TB in Msinga: Summary • The commitment of the Umzinyathi health district management team ensured that TB control was placed at the top of Drug resistant tuberculosis has emerged as a serious public the district’s agenda and that adequate resources health issue around the world. Recent global estimates put were allocated to tackle the number of reported cases for 2006 at close to half a the disease. million. This represents 4.8 percent of all notified TB cases • The management of TB worldwide. An estimated 1.5 million people died from TB in patients was aggressively 2006. addressed by providing In 2006, an outbreak of a deadly and almost incurable refresher training for form of TB was reported in Msinga, Umzinyathi district, a nurses and introducing remote and rural part of KwaZulu-Natal province in South appointment diaries to Africa. The extensively drug-resistant TB or ‘XDR TB’ as it track patients. became known largely occurred among HIV-infected • An increase in the nurse- people, in particular those with terminal AIDS. to-patient ratio also played Patients who were co-infected with XDR TB and HIV an important role in improv- stood little chance of survival.
    [Show full text]
  • Tuberculosis in Infants Less Than 3 Months Ofage
    Archives of Disease in Childhood 1993; 69: 371-374 371 Tuberculosis in infants less than 3 months of age Arch Dis Child: first published as 10.1136/adc.69.3.371 on 1 September 1993. Downloaded from H S Schaaf, R P Gie, N Beyers, N Smuts, P R Donald Abstract identified from a register of cases proved by The clinical and radiological features in 38 culture. infants less than 3 months of age with A history of contact with adult pulmonary tuberculosis proved by culture are tuberculosis, the presenting symptoms and described and may aid early diagnosis of their duration, and clinical features such as this often fatal condition. Respiratory lymphadenopathy, respiratory signs, and the symptoms, cough in 33 (87%) and tachyp- presence of hepatosplenomegaly were noted. noea in 31 (82%), were the commonest Tuberculin testing was either by Mantoux test presenting symptoms. Twenty five infants 5 units purified protein derivative or Tine test (66%) had hepatomegaly and 20 (53%) (Lederle) with an induration of > 15 mm or a splenomegaly. Mantoux testing gave an confluent reaction respectively being regarded induration of >15 mm in three of 17 (18%) as significant. infants. In a further five a Tine test gave The chest radiographs of 27 (71%) of the 38 confluent response. Chest radiography in infants were assessed systematically by a panel 27 infants showed miliary tuberculosis in consisting of all the authors. Particular seven (26%) and hilar or paratracheal attention was paid to the presence of miliary adenopathy in 14 (52%) and 10 (37%) tuberculosis, the presence of hilar or para- respectively.
    [Show full text]
  • TB Policies in 24 Countries a Survey of Diagnostic and Treatment Practices About Médecins Sans Frontières
    Out of Step 2015 TB Policies in 24 Countries A survey of diagnostic and treatment practices About Médecins Sans Frontières Médecins Sans Frontières (MSF) is an independent international medical humanitarian organisation that delivers medical care to people affected by armed conflicts, epidemics, natural disasters and exclusion from healthcare. Founded in 1971, MSF has operations in over 60 countries today. MSF has been involved in TB care for 30 years, often working alongside national health authorities to treat patients in a wide variety of settings, including chronic conflict zones, urban slums, prisons, refugee camps and rural areas. MSF’s first programmes to treat multidrug-resistant TB opened in 1999, and the organisation is now one of the largest NGO treatment providers for drug-resistant TB. In 2014, the organisation started 21,500 patients on first-line TB treatment across projects in more than 20 countries, with 1,800 patients on treatment for drug-resistant TB. About the MSF Access Campaign In 1999, on the heels of MSF being awarded the Nobel Peace Prize – and largely in response to the inequalities surrounding access to HIV/AIDS treatment between rich and poor countries – MSF launched the Access Campaign. Its sole purpose has been to push for access to, and the development of, life- saving and life-prolonging medicines, diagnostics and vaccines for patients in MSF programmes and beyond. About Stop TB Partnership The Stop TB Partnership is leading the way to a world without TB, a disease that is curable but still kills three people every minute. Founded in 2001, the Partnership’s mission is to serve every person who is vulnerable to TB and to ensure that high-quality treatment is available to all who need it.
    [Show full text]
  • Health Care Provider Information
    Health Care Provider Information NOTE: This page is a resource for Whatcom County clinicians dealing with tuberculosis: recognizing active disease and screening for and treating latent infection. The Whatcom County Health Department provides this as a tool/resource in our collaboration with community clinicians, and we welcome feedback and suggestions for additions and changes that improve its usefulness. (Contact Info) Distinguishing Active TB Disease from Latent Infection TB life cycle/Transmission: Tuberculosis (TB) is a disease caused by bacteria (Mycobacteria tuberculosis, or Mtb) transmitted from people with active pulmonary or laryngeal TB disease as aerosolized particles that are suspended in air. Other people may inhale these infectious particles and become infected with Mtb. In the vast majority of cases, their immune system responds to the infection and walls it off, resulting in a latent tuberculosis infection with no disease (and not contagious). When the infected person is immunosuppressed (e.g., HIV/AIDS) or has an immature immune system (young child), the infection may progress to primary active disease without latency. Immune response: The asymptomatic, noncontagious cases are identified by measuring their immune response to tuberculosis, using a TB skin test (TST) or a blood test (interferon gamma release assay, or IGRA). Progression to disease: About 5% of those with latent infection progress to active tuberculosis disease in the first two years after becoming infected. The risk for progression after that is about 0.1% per year (1% per decade of remaining lifetime). The risk of progression increases with conditions that suppress the immune system. This progression can occur with initial infection (primary disease) or after a latent period (reactivation disease).
    [Show full text]
  • Chapter 5 Diagnosis of Latent Tuberculosis Infection (LTBI)
    Chapter 5 Diagnosis of Latent Tuberculosis Infection (LTBI) CONTENTS Introduction ............................................. 5.2 Purpose................................................................ 5.2 Policy ................................................................... 5.2 Tuberculosis Classification System ..... 5.3 High-Risk Groups ................................... 5.4 Diagnosis of Latent Tuberculosis Infection ........................... 5.5 Interferon gamma release assays ........................ 5.5 Selecting a TB screening Test ............................. 5.6 Mantoux tuberculin skin testing ........................... 5.7 Candidates for Mantoux tuberculin skin testing ........................................................... 5.8 Administration of the tuberculin skin test ........... 5.11 Measurement of the tuberculin skin test ........... 5.13 Interpretation of the tuberculin skin test ............. 5.14 Human immunodeficiency virus screening ........ 5.16 Follow-up activities ............................................. 5.16 Chest radiography .............................................. 5.16 Resources and References ................. 5.19 NEVADA TUBERCULOSIS PROGRAM MANUAL Diagnosis of Latent Tuberculosis Infection 5 . 1 R e v i s e d A P R I L 2 0 1 8 Introduction Purpose Use this section to understand and follow national and Nevada State guidelines to do the following: ▪ Classify patients with latent TB infection (LTBI). ▪ Diagnose LTBI. In the 2005 guideline “Controlling Tuberculosis in the United States:
    [Show full text]
  • Tuberculin Testing: Its Basis, Methods, and Comparative Results
    Tuberculin testing: Its basis, methods, Tuberculin test and comparative results DOUGLAS P. HAGEN, D.O. Kirksville, Mo. Several procedures for administering test has converted to positive. Several methods tuberculin for skin testing of performing tuberculin skin tests will be re- viewed, and the results of the methods will be are reviewed. The Mantoux test is compared. considered the most accurate, in that the test dose can be measured Basis for tuberculin testing accurately, the equipment and During the first infection with the tubercle materials required are available readily, bacillus, the host acquires hypersensitivity to the organism. Hypersensitivity can be induced and the reactions can be read by the whole tubercle bacillus alone or a and recorded quantitatively. Its chief combination of the wax fraction of the or- disadvantage is the skill required ganism containing a lipopolysaccharide and to administer the test. Multiple-puncture tuberculoprotein but not by tuberculoprotein techniques need minimal skill alone. The reaction that occurs when an anti- for administration and false negative gen to tuberculosis is introduced intradermally provides a valuable testing procedure for both reactions are rare. However, the epidemiologic and case finding purposes. tuberculins are not well standardized, Tuberculin testing material is basically of the dose of tuberculin two types, old tuberculin (OT) and purified retained in the skin is unknown, and protein derivative (PPD). Old tuberculin is false positive reactions may a concentrated filtrate of broth in which tu- occur. Because of the variables affecting bercle bacilli have grown for 6 weeks. Cultures of Mycobacterium tuberculosis are heat-ster- the dose, quantitative measures ilized.
    [Show full text]
  • Revised 3.11, 9.11, 4.12, 11.13, 5.14, 11.15, 5.16, 8.16, 6/21 Butler
    Butler Community College Department of Nursing Health Requirement Frequently Asked Questions The clinical agencies with which we are affiliated have policies requiring an annual physical exam, immunizations and TB screening for all nursing students. The following must be completed before the first day of class. The health forms, CPR, and immunizations need to be completed and to College Health on or before the first day of class. If you have questions, please contact College Health Services (322-3371 or 218-6282). Butler Health Form must be completed within the last 3 months and signed by a physician (MD or DO), physician assistant (PA) or nurse practitioner (APRN). If you are an EMT, LPN or CNA and took the Butler IV Therapy, EMT, or CNA course the semester prior to your admission, the 3- month deadline will be waived, but must be within the last year and will be repeated annually. Immunization record (on back of Butler Health Form) o It must be signed in the lower left-hand corner of the form by a health care provider. Immunization record must include the following documentation: o Tetanus (Tdap) within the past 10 years. o Hepatitis B series, a signed refusal form, or positive titer. o Two MMR's (unless you were born before 1957) at least one month apart or a positive titer for measles, mumps, and rubella. o A positive Varicella (chickenpox) Titer o TB skin testing must be completed prior to Varicella and MMR vaccines. o Verification of TB test – Documentation on the immunization form . Students entering the Butler nursing program for the first time must show documentation of a 2-Step TB Skin Test OR QuantiFERON Gold or TSpot (blood test).
    [Show full text]
  • Childhood Tuberculosis with Reference to the Ameriean Indian
    Childhood Tuberculosis With Reference to the Ameriean Indian HELEN M. WALLACE, M.D., M.P.H. PROGRESS has been made in times that of the United States as a whole. Of GREATreducing deaths from tuberculosis in the the total cases reported in 1964, nearly 38 per¬ United States over the past decades, but the cent were in persons less than 20 years old greater challenge of eradication remains. From (table 2). 1900 to 1960 the tuberculosis death rate declined Since 1956 fewer patients with tuberculosis from 194.1 to 6.1 per 100,000 persons (1). have been hospitalized and their hospital stays Striking decreases in the rate occurred during have been shorter. In 1965 the tuberculosis the early years of the 20th century and in the patient census constituted about 17 percent of years 1946-55 following discovery of the chemo- the total census for all types of patients. This therapeutic and antibiotic compounds isoniazid was a decrease of 76 percent in census from the and streptomycin. peak in 1956 (3). The ambulatory chemo- For many decades the rate of deaths due to therapy program contributed to a marked de¬ tuberculosis has been higher among the non- cline in hospitalization, and the use of drugs white than in the white population. In 1960 also helped to reduce the length of stay of among white infants, children, and youth, mor¬ patients requiring hospitalization. tality rates from tuberculosis were low; for the comparable nonwhite age groups mortality Mortality Among Indians rates were significantly higher (table 1). The The highest tuberculosis death rate in the ratio of deaths of nonwhite to white persons United States has been among Ameriean In¬ from tuberculosis in 1960 was 2.8 to 1.
    [Show full text]
  • A Reference Booklet for Practitioners on Basic Tuberculosis
    DecemberDecember 20062006 Dear Medical Practitioner and Health Care Worker, This booklet provides basic information on the diagnosis, treatment, and management of latent tuberculosis infection and tuberculosis disease, based on recommendations from the Centers for Disease Control and Prevention (CDC), the Infectious Disease Society, and the American Thoracic Society. Because we cover the basic considerations only, all health care workers involved in tuberculosis care are encouraged to call consultants at the Regional Medical Consultation Center that serves your region. (See list of contact information in front of Book) Sincerely, David E. Griffi th, M.D. Barbara J. Seaworth, M.D. Assistant Medical Director Director, Heartland National TB Center Heartland National TB Center Professor of Medicine Professor of Medicine University of Texas Health Center, Tyler University of Texas Health Center, Tyler Email: Email: david.griffi [email protected] [email protected] TB Education and Training: Toll-Free # for Health Care Providers: (800) 839-5864 or (800) 428- 7432 FAX: 210-531-4590 REPORTING: Physicians are required to report suspected or confi rmed cases of tuberculosis according to pertinent State Law, such as the State of Texas Health & Safety Code Section 97.4.b. Information about TB reporting in states other than Texas can be obtained from the state TB controller. According to the State of Texas Health & Safety Code, Section 97.4.b., it is the physician’s responsibility to report all cases of tuberculosis disease, whether suspected or confi rmed, to the local health authority within one working day of diagnosis. Note: The information in this booklet was originally published by the New York City Bureau for Tuberculosis Control.
    [Show full text]
  • Mantoux Tuberculin Skin Testing
    Mantoux Tuberculin Skin Testing A Training Guide New Jersey Medical School Global Tuberculosis Institute 225 Warren Street Newark, New Jersey 07101-1709 Phone: 973.972.0979 Fax: 973.972.1064 Website: http://www.umdnj.edu/globaltb Mantoux Tuberculin Skin Testing Training Guide Acknowledgments The New Jersey Medical School Global Tuberculosis Institute wishes to acknowledge the following organizations and individuals for their contribution to this project: Lawrence D. Budnick, MD University of Medicine & Dentistry of New Jersey – New Jersey Medical School Newark, NJ BeverlyAnn Collins, RN, CIC University of Medicine & Dentistry of New Jersey – University Hospital Newark, NJ Francis J. Curry National Tuberculosis Center San Francisco, California Florida Department of Health A.G. Holley State Hospital Lantana, Florida Christy Heston, LVN Tarrant County Corrections Fort Worth, TX Ronald J. Karpick, MD Fairfax County Health Department Falls Church, VA Suzanne S. Klatt, RN, MSN Detroit Medical Center Detroit, MI Document Prepared by: Anita Khilall and Rajita Bhavaraju Graphic Design: Alfred Paspe All material in this document is in the public domain and may be used and reprinted without special permission; citation of source, however, is appreciated: Suggested citation: New Jersey Medical School Global Tuberculosis Institute. Mantoux Tuberculin Skin Testing Training Guide. 2007 (inclusive pages). The New Jersey Medical School Global Tuberculosis Institute is a joint project of the UMDNJ- New Jersey Medical School and the New Jersey Department
    [Show full text]
  • The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa Global and Local Challenges and Solutions
    The Emerging Threat of Drug-Resistant Tuberculosis in Southern Africa Global and Local Challenges and Solutions Summary of a Joint WorkShop by the Institute of Medicine and the Academy of Science of South Africa Steve Olson, Yeonwoo Lebovitz, and Anne Claiborne, Rapporteurs Forum on Drug Discovery, Development, and Translation Board on Health Sciences Policy and ACADEMY OF SCIENCE OF SOUTH AFRICA THE NATIONAL ACADEMIES PRESS 500 Fifth Street, N.W. Washington, DC 20001 NOTICE: The project that is the subject of this report was approved by the Govern- ing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineer- ing, and the Institute of Medicine. This study was supported by Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and 223001003T), the U.S. State Department (S-LMAQM- 08-GR-071), the American Diabetes Association, the American Society for Micro- biology, Amgen Inc., the Association of American Medical Colleges, Bristol-Myers Squibb, the Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, the Critical Path Institute, the Doris Duke Charitable Foundation, Eli Lilly & Co., GlaxoSmithKline, Howard Hughes Medical Institute, Johnson & Johnson, Novartis Pharmaceuticals Corporation, and Pfizer, Inc. Any opinions, findings, conclusions, or recommenda- tions expressed in this publication are those of the author(s) and do not necessarily reflect the view of the organizations or agencies that provided support for this project. International Standard Book Number-13: 978-0-309-16024-7 International Standard Book Number-10: 0-309-16024-3 Additional copies of this report are available from the National Academies Press, 500 Fifth Street, N.W., Lockbox 285, Washington, DC 20055; (800) 624-6242 or (202) 334-3313 (in the Washington metropolitan area); Internet, http://www.nap.edu.
    [Show full text]
  • Squamous Cell Carcinoma Arising from Long-Term (50-Year)
    Le Infezioni in Medicina, n. 4, 249-253, 2009 Casi clinici Squamous cell carcinoma arising from long-term Case reports (50-year) Lupus vulgaris: is there a need for a close medical follow-up in such chronic diseases? Lupus vulgaris: evoluzione in carcinoma squamocellulare dopo 50 anni: e se fosse necessario un follow-up più stretto? Pietro Leocata1, Giuliana Crisman1, Anna Rita Vitale1, Giovanni Siniscalchi2, Paolo Biondi2, Giuseppe Colella2 1Pathology Unit, Department of Health Sciences, University of L’Aquila, Italy; 2Second University of Naples, Department of Head and Neck Surgery, Naples, Italy n INTRODUCTION lesion in the same region since she was 19-year- old, first diagnosed as an abscess and partially uberculosis is a systemic infectious disease resolved with antibiotics. The persistence of the caused by Mycobacterium tuberculosis. lesion led the General Practitioner to suggest TAlthough this infection showed a remark- the diagnosis of angioma; thus the patient un- ably decline in past decades, the immigration phe- derwent electrodesiccation therapy. Ten years nomenon and the increasing number of patients later, the recurrence of the lesion led to a clini- affected by acquired immunodeficiency syn- cal diagnosis of LV and an anti-tuberculosis dromes could explain the well-established in- therapy was instituted with Etanicozid B6 (a crease in incidence observed in European coun- combination of ethambutol-400 mg, isoniazid- tries. Lupus vulgaris (LV) represents the most com- 125 mg, pyridoxine-50 mg) three capsules per mon cutaneous manifestation of tuberculosis. day and rifamycin (locally administered), with Even if it is a rare condition, squamous cell carci- a slight improvement.
    [Show full text]